[Development of cancer-specific monoclonal antibodies against glycoproteins]

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Traditional monoclonal antibody (mAb) production faces challenges in identifying specific cancer targets due to shared antigen expression in normal tissues.
• High tumor/normal antigen expression ratios are crucial for antibody-drug development but often limited by normal tissue expression.
• Existing methods struggle to differentiate cancer cells from normal cells based solely on protein sequence.

Purpose of the Study:

• To introduce a novel technology for producing cancer-specific monoclonal antibodies (CasMabs).
• To leverage post-translational modifications, such as glycosylation, for cancer cell targeting.
• To develop therapeutic antibodies that selectively target cancer cells, minimizing off-target effects.

Main Methods:

• Established a novel CasMab technology utilizing post-translational differences (e.g., glycans) for antibody generation.
• Produced CasMabs against glycoproteins like podoplanin, which exhibit differential expression patterns in cancer.
• Validated CasMab efficacy through in vitro cytotoxicity assays (ADCC, CDC) and in vivo xenograft models.

Main Results:

• Successfully produced CasMabs targeting cancer-specific post-translational modifications.
• Demonstrated that CasMabs induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in vitro.
• Observed significant anti-tumor effects in vivo using xenograft models, confirming CasMab efficacy.

Conclusions:

• CasMab technology provides a platform for developing cancer-specific monoclonal antibodies.
• This approach enables the selective targeting of cancer cells by exploiting unique post-translational differences.
• CasMabs offer a promising strategy for cancer therapy with the potential to minimize side effects on normal tissues.